Beijing GoBroad Boren Hospital
This study integrates multiple diseases, breaking down their causes, symptoms, and key diagnostic and treatment points.
Hospital Overview
Beijing GoBroad Boren Hospital is the Beijing Research Center of GoBroad Medical Group (Hematology) and the group’s first flagship hospital, established in Beijing in 2017. Located in Fengtai District, the hospital is a Class II comprehensive hospital and a designated medical insurance institution in Beijing.
The hospital specializes in hematological oncology, Parkinson’s disease, liver cancer, and comprehensive inpatient care. Its core strengths include CAR-T cell immunotherapy, hematopoietic stem cell transplantation, and the diagnosis and treatment of complex hematological diseases.
City
Fengtai District, Beijing, China
Hospital Positioning
GoBroad Medical Group’s first flagship hospital and Beijing Research Center for Hematology
Regional Medical
Class II comprehensive hospital and designated medical insurance institution in Beijing
Inpatient Beds
Class 100 Laminar Flow Rooms
Hospital Area
Year Established
Core treatment areas
Routine diagnosis and treatment
Comprehensive diagnosis and treatment of adult and pediatric hematological diseases, including leukemia, lymphoma, multiple myeloma, thalassemia, and thrombocytopenia. The hospital also provides CAR-T cell immunotherapy, hematopoietic stem cell transplantation, targeted therapy, and comprehensive inpatient services.
Diagnosis and Treatment of Complex and Severe Cases:
Specialized treatment for refractory and relapsed hematological malignancies, including leukemia, lymphoma, and multiple myeloma. The hospital provides sequential CAR-T therapy, CAR-T bridging transplantation, second allogeneic transplantation, and treatment of severe transplantation complications, including graft-versus-host disease (GVHD) and infections.
Authoritative Qualifications and International Medical Collaboration
Clinical research qualifications, international expert collaboration, and specialized diagnostic capabilities support comprehensive hematological care.
Global Partnerships
International experts from Mayo Clinic serve as consulting specialists at the hospital.
Experts from MD Anderson Cancer Center have been appointed as consulting specialists.
Specialized Qualifications
Specialty Centers & Core Medical Sciences
Specialized hematology, oncology, transplantation, and integrated diagnostic services supported by experienced clinical teams.
HEM
Hematology/Oncology Department
HSCT
Hematopoietic Stem Cell Transplantation
PED
Pediatric Hematology/Oncology
IDC
Integrated Diagnostic Center
Hematology/Oncology Department
Department Overview
The Hematology/Oncology Department is one of the key departments of Beijing GoBroad Boren Hospital, led by Director Tong Chunrong, one of the earliest experts in immunotherapy in China. The department provides diagnosis and treatment for various types of adult and pediatric hematologic diseases, including hematological malignancies such as leukemia, lymphoma, and multiple myeloma, anemia diseases such as thalassemia, and bleeding/coagulation disorders such as thrombocytopenia.
Core Technologies
CAR-T Cell Immunotherapy: One of the teams with the most CAR-T targets and the highest number of treated patients among single centers internationally, with CAR-T targets including CD4, CD7, CD19, CD20, CD22, CD30, CD33, CD70, CD79b, BCMA, GPRC5D, etc.
Sequential CAR-T Therapy: Expert in sequential CAR-T therapy to improve long-term progression-free or relapse-free survival rates.
Integrated Diagnostic Technology: Comprehensive diagnostics integrating cytomorphology, flow cytometry, chromosome and FISH analysis, genetic analysis, pathogen testing, and drug concentration monitoring.
Targeted Therapy: Targeted medication guidance based on NGS testing, implementing treatment strategies of “same treatment for different diseases, different treatment for same disease.”
Minimal Residual Disease (MRD) Monitoring: MRD monitoring through flow cytometry analysis, real-time quantitative PCR, and site-specific variant gene deep sequencing quantification.
Neoantigen Immunotherapy: Development of neoantigen immunotherapy for treating hematological tumors and solid tumors.
Dr. Tong Chunrong
Research Director / Chief Physician / Director of Hematology Department 1
Areas of expertise:
- Integrated diagnosis and treatment of hematological malignancies.
- CAR-T cell immunotherapy for refractory and relapsed hematological tumors.
- Targeted therapy and comprehensive hematological oncology care.
Hematopoietic Stem Cell Transplantation
Department Overview
The Hematology Department 2 (Hematopoietic Stem Cell Transplantation Department) is led by Director Wu Tong, bringing together a team of hematopoietic stem cell transplantation experts with extensive experience in both adult and pediatric transplantation, with excellent theoretical and clinical capabilities. The discipline leader has 26-30 years of experience in hematopoietic stem cell transplantation, having completed over 4,000 allogeneic hematopoietic stem cell transplantations.
Core Technologies
Allogeneic Hematopoietic Stem Cell Transplantation: Having completed thousands of cases, covering various transplantation methods including matched sibling, unrelated donor, haploidentical, cord blood, syngeneic, and autologous transplantation.
CAR-T Bridging Transplantation: Sequential transplantation after CAR-T remission significantly improves disease-free survival rates.
Second Allogeneic Transplantation: Outstanding achievements in second allogeneic transplantation with disease-free survival rate of 72.5%.
Elderly Leukemia Transplantation: Extensive experience in adult (up to 72 years old) and pediatric (as young as 1 month old) transplantation.
Individualized Preconditioning Regimen: Developing individualized preconditioning regimens based on patient conditions.
Transplantation Complication Prevention and Treatment: Extensive experience in treating severe GVHD and infections.
Dr. Wu Tong
Medical Director / Chief Physician / Director of Hematology Department 2
Areas of expertise:
- Allogeneic hematopoietic stem cell transplantation.
- CAR-T bridging transplantation and second allogeneic transplantation.
- Treatment of severe GVHD, infections, and post-transplantation relapse.
Pediatric Hematology/Oncology
Department Overview
The Pediatric Hematology/Oncology Department is led by Director Zhang Yonghong, specializing in the diagnosis and treatment of various pediatric hematological and oncological diseases. In 2003, she established and became the discipline leader of the Lymphoma Division at Beijing Children’s Hospital. In 2017, she established and became the group leader of the National Pediatric Lymphoma Collaboration Group (CNCL). She pioneered the application of internationally-aligned refined stratified chemotherapy protocols in China, increasing the overall cure rate of pediatric lymphoma to 80-90%.
Core Technologies
Refined Stratified Chemotherapy: Pioneered the application of internationally-aligned refined stratified chemotherapy protocols in China.
CD19/CD20/CD22 Sequential CAR-T Cell Therapy: Globally pioneered the first application of sequential CD19/CD20/CD22 CAR-T cell infusion for treating pediatric refractory/relapsed Burkitt lymphoma.
Pediatric Lymphoma Targeted Therapy and Immunotherapy: Innovative explorations in pediatric lymphoma targeted therapy and immunotherapy.
National Pediatric Lymphoma Collaboration Group (CNCL): Collaboration group has expanded to 43 tertiary hospitals in provinces and cities.
CNCL-B-NHL-2017 Protocol: Improved based on LMB89/96 protocol, increasing 2-year overall survival rate to 93.4%.
MDT (Multidisciplinary Team) Diagnosis and Treatment: Developing optimal treatment plans for patients through multidisciplinary team collaboration.
Dr. Zhang Yonghong
Medical Director / Professor / Director of Hematology Department 3
Areas of expertise:
- Diagnosis and treatment of pediatric hematological and oncological diseases.
- Pediatric lymphoma and refined stratified chemotherapy.
- Sequential CAR-T cell therapy for refractory and relapsed pediatric lymphoma.
Integrated Diagnostic Center
Department Overview
The Integrated Diagnostic Center of Beijing GoBroad Boren Hospital is a comprehensive clinical diagnostic center integrating medical services, teaching, and research, led by an expert team with over 30 years of experience in testing and diagnostic research. Covering an area of 5,000 square meters, it is one of the few precision diagnostic collaboration laboratories in China for ThermoFisher, a global leader in laboratory construction.
Core Technologies
Pathology and MICM Integrated Diagnosis Model: Using pathology (P), morphology (M), immunology (I), cytogenetics (C), and molecular biology (M) as core technologies.
Cytomorphology Testing: Peripheral blood smear/bone marrow cytology, bone marrow biopsy/tissue pathology/consultation, special staining, and enzyme histochemistry.
Flow Cytometry Testing: Equipped with advanced BD and Beckman Coulter flow cytometers for leukemia and lymphoma flow cytometry-related testing.
Chromosome and FISH Testing: High-resolution chromosome banding karyotype analysis, chromosome FISH testing.
Molecular Diagnosis: Fusion gene testing, gene mutation testing, MRD testing, transplantation-related molecular testing.
Drug Concentration Monitoring: Monitoring of 22 types of drugs including immunosuppressants, antiepileptic drugs, and antifungal drugs.
Advantages of cutting-edge diagnostic and treatment technologies :
- CAR-T Cell Immunotherapy
CAR-T cell immunotherapy for refractory and relapsed hematological malignancies, with multiple therapeutic targets including CD19, CD20, CD22, BCMA, and GPRC5D.
- Multi-target CAR-T therapy / Hematological malignancies
- Hematopoietic Stem Cell Transplantation
Comprehensive transplantation services for adult and pediatric patients, including allogeneic transplantation, CAR-T bridging transplantation, and second allogeneic transplantation.
- Individualized transplantation / Post-transplantation care
- Integrated Hematological Diagnostics
Comprehensive diagnosis integrating cytomorphology, flow cytometry, chromosome and FISH analysis, genetic testing, and molecular diagnostics.
- Integrated diagnostic technologies / Precision hematology
- Minimal Residual Disease Monitoring
MRD monitoring through flow cytometry, real-time quantitative PCR, and site-specific variant gene deep sequencing to support hematological disease assessment.
- MRD monitoring / Molecular diagnostics
Multidisciplinary Care for Complex Hematological Diseases
The hospital provides multidisciplinary diagnosis and treatment for complex hematological diseases, integrating expertise in hematology, oncology, transplantation, immunotherapy, and specialized laboratory diagnostics.
Multidisciplinary collaboration supports individualized treatment planning for patients with refractory and relapsed hematological malignancies, including those requiring CAR-T cell therapy, hematopoietic stem cell transplantation, and comprehensive diagnostic assessment.
Modern Medical Facilities and Patient-Centered Care
Specialized hematology facilities, advanced diagnostic equipment, and dedicated inpatient environments support comprehensive medical care.
Hospital Environment
High-end medical equipment
Flow Cytometer
Advanced flow cytometry equipment supports hematological disease diagnosis, immunophenotyping, and minimal residual disease monitoring.
PCR Amplifier
PCR amplification equipment supports molecular diagnostics and genetic testing for hematological diseases.
Blood Cell Separator
Blood cell separation equipment supports specialized hematological treatment and clinical procedures.
Specialized Inpatient Facilities
- 170 inpatient beds.
- 19 Class 100 laminar flow rooms.
- Laminar flow clean rooms designed for hematopoietic stem cell transplantation patients.
- Class 100 operating rooms and intensive care units.
Patient Accommodation Options
- Wanda Realm Beijing Fengtai — approximately 10 minutes by car.
- Atour Hotel Beijing Lize — approximately 8 minutes by car.
- Hanting Hotel Beijing Fengtai — approximately 5 minutes by car.
Location and Transportation
Located in Beijing's Fengtai District, the hospital is accessible by subway, bus, private car, and major international airports.
Hospital Address
Building A/B/C, Longwei Plaza, Jitong East Road, Fengtai District, Beijing, China.
Airport Transportation
Beijing Capital International Airport
Approximately 40 kilometers from the hospital.
Approximately 60 minutes by car
Beijing Daxing International Airport
Approximately 50 kilometers from the hospital.
Approximately 50 minutes by car
Accommodation
Wanda Realm Beijing Fengtai
International five-star hotel.
10-minute drive
¥800–1,800/night
Atour Hotel Beijing Lize
Mid-range business hotel.
8-minute drive
¥400–700/night
Hanting Hotel Beijing Fengtai
Economy hotel.
5-minute drive
¥250–400/night
City Transportation
Subway
Take Metro Line 10 to Jijiamiao Station. Exit the station and follow the signs for Boren Hospital for approximately 200 meters, then turn right at the T-intersection.
Bus
Take a bus to Yuquanying Bridge West Station. Walk south for approximately 500 meters from the intersection near Chenmao Nanyueyuan Hotel to reach the hospital.
Self-Driving
Take the South Third Ring Road auxiliary road, turn right approximately 350 meters east of Wanliu Bridge, and continue south for approximately 500 meters from the intersection near Chenmao Nanyueyuan Hotel.
Surrounding Amenities
Huaxiang Community Health Service Center
Nearby medical facility
Renkang Youxuan Zhipin Supermarket
Nearby supermarket
Kangcheng Badminton Hall
Nearby recreational facility
Line 10 Creative Park
Nearby leisure destination
Jijiamiao Park
Nearby public park
Get Your Free No-obligation Medical
Consultation Now